Literature DB >> 2506671

Heparin induced increase of t-PA antigen plasma levels in patients with unstable angina: no evidence for clinical benefit of heparinization during the initial phase of treatment.

K Huber1, I Resch, D Rosc, P Probst, F Kaindl, B R Binder.   

Abstract

Patients with unstable coronary artery disease were randomly treated either with a combination therapy consisting of nitrates and calcium-channel blockers without or with addition of clinical grade heparin administered subcutaneously; in order to evaluate the effect of heparin treatment on the fibrinolytic system, tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) plasma levels were related to the clinical course of the disease. In heparinized patients thrombin time was prolonged more than 3-fold the normal range indicating effective heparin treatment. Heparinization led to a significant increase in t-PA antigen plasma levels (p less than 0.0001) within approximately four hours while PAI-1 activities remained unaltered. However, the measurable increase of the anticoagulant and pro-fibrinolytic activities of heparin did not result in a short-term benefit for the heparinized patients because the number of further ischemic attacks per patient during the observation period of three days was not different between the two study groups.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2506671     DOI: 10.1016/0049-3848(89)90308-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  2 in total

Review 1.  Heparin versus placebo for non-ST elevation acute coronary syndromes.

Authors:  Carlos A Andrade-Castellanos; Luis E Colunga-Lozano; Netzahualpilli Delgado-Figueroa; Kirk Magee
Journal:  Cochrane Database Syst Rev       Date:  2014-06-27

2.  A non-circulating pool of factor XI associated with glycosaminoglycans in mice.

Authors:  Bassem M Mohammed; Qiufang Cheng; Anton Matafonov; Ingrid M Verhamme; Jonas Emsley; Keith R McCrae; Owen J T McCarty; Andras Gruber; David Gailani
Journal:  J Thromb Haemost       Date:  2019-06-17       Impact factor: 16.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.